Results 11 to 20 of about 378 (67)

Enhanced Activities of OCT4 and SOX2 Promote Epigenetic Reprogramming by Shortening G1 Phase. [PDF]

Adv Sci (Weinh)
Fusing the VP16 domain to OCT4 and SOX2 (OvSvK) enhances iPSC generation by activating downstream targets, including those regulating the cell cycle. This accelerates reprogramming by shortening the G1 phase and reducing H3K27me3 levels. Modulating Ccnd1, Cdkn2a, and Ccne1 improves efficiency, linking cell cycle to epigenetic remodeling.
Guo L, Lin J, Ren Q, Sun H, Wu Y, Ge H, Wu X, Lin L, Liang L, Li C, Liu H, Mai Y, Chu S, Liu J, Liu J, Chen J, Pei D, Zheng H.   +17 more
europepmc   +2 more sources

Serum Proteomic and Metabolomic Signatures of High Versus Low Physical Function in Octogenarians. [PDF]

Aging Cell
Circulating factors are strongly implicated in modulating biological aging. In this study we show that the serum proteomic and metabolomic profile of high functioning octogenarians suggests lower activation of SASP, preservation of the tryptophan‐kynurenic pathway, higher lipophosphatidyl cholines promoting mitochondrial function, and reduced ...
Ubaida-Mohien C, Moaddel R, Spendiff S, MacMillan NJ, Filion ME, Morais JA, Candia J, Fitzgerald LF, Taivassalo T, Coen PM, Ferrucci L, Hepple RT.   +11 more
europepmc   +2 more sources

The Concise Guide to PHARMACOLOGY 2023/24: Enzymes

British Journal of Pharmacology, Volume 180, Issue S2, Page S289-S373, October 2023., 2023
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands.
Stephen P. H. Alexander, Doriano Fabbro, Eamonn Kelly, Alistair A. Mathie, John A. Peters, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jurg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +28 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

British Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Doriano Fabbro, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Stephanie Annett, Detlev Boison, Kathryn Elisa Burns, Carmen Dessauer, Jürg Gertsch, Nuala Ann Helsby, Angelo A. Izzo, Rennolds Ostrom, Ester Pagano, Andreas Papapetropoulos, Nigel J. Pyne, Susan Pyne, Tracy Robson, Roland Seifert, Johannes‐Peter Stasch, Csaba Szabo, Mario van der Stelt, Albert van der Vliet, Val Watts, Szu Shen Wong   +31 more
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Transporters

British Journal of Pharmacology, Volume 182, Issue S1, Page S404-S496, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander, Alasdair J. Gibb, Eamonn Kelly, Alistair A. Mathie, Chloe J. Peach, Emma L. Veale, Jane F. Armstrong, Elena Faccenda, Simon D. Harding, Christopher Southan, Jamie A. Davies, Laura Amarosi, Catriona M. H. Anderson, Philip M. Beart, Stefan Broer, Paul A. Dawson, Gergely Gyimesi, Bruno Hagenbuch, James R. Hammond, Jules C. Hancox, Michal Hershfinkel, Ken‐ichi Inui, Yoshikatsu Kanai, Stephan Kemp, Edmund R. S. Kunji, Gavin Stewart, Sotiria Tavoulari, David T. Thwaites, Tiziano Verri   +28 more
wiley   +1 more source

Cannabinoid CB2 receptor‐mediated analgesia: mechanism‐based insights and therapeutic potential

British Journal of Pharmacology, Volume 182, Issue 21, Page 5090-5118, November 2025.
Agonists of the cannabinoid 2 (CB2) receptor have shown promise for the treatment of pain in a variety of animal models. However, despite current preclinical evidence supporting the use of CB2 agonists for pain, successful translation of findings from preclinical models to human patients is lacking.
Kelsey G. Guenther, Andrea G. Hohmann
wiley   +1 more source

Leukocyte count and new‐onset diabetes mellitus in people with HIV: A longitudinal study

HIV Medicine, Volume 26, Issue 10, Page 1585-1599, October 2025.
Abstract Objectives The risk of diabetes mellitus (DM) is increased in people with HIV. Chronic inflammation contributes to DM risk. High leukocytes are associated with DM in the general population, but in people with HIV, evidence of a leukocyte–DM association is limited. Methods We included participants of the Swiss HIV Cohort Study with new‐onset DM
Sophia C. Meyer, Zoe Klein, Isabella C. Schoepf, Christian W. Thorball, Marco Labarile, Neeltje A. Kootstra, Peter Reiss, Lene Ryom, Dominique L. Braun, Maria C. Thurnheer, Catia Marzolini, Christian R. Kahlert, Enos Bernasconi, Matthias Cavassini, Annalisa Marinosci, Jacques Fellay, Huldrych F. Günthard, Roger D. Kouyos, Bruno Ledergerber, Philip E. Tarr, the Swiss HIV Cohort Study, I Abela, K Aebi‐Popp, A Anagnostopoulos, M Battegay, E Bernasconi, DL Braun, HC Bucher, A Calmy, M Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer, CA Fux, HF Günthard, A Hachfeld, D Haerry, B Hasse, HH Hirsch, M Hoffmann, I Hösli, M Huber, D Jackson‐Perry, patient representatives, CR Kahlert, O Keiser, T Klimkait, RD Kouyos, H Kovari, K Kusejko, N Labhardt, K Leuzinger, B Martinez de Tejada, C Marzolini, KJ Metzner, N Müller, J Nemeth, D Nicca, J Notter, P Paioni, G Pantaleo, M Perreau, A Rauch, L Salazar‐Vizcaya, P Schmid, R Speck, M Stöckle, P Tarr, A Trkola, G Wandeler, M Weisser, S. Yerly   +75 more
wiley   +1 more source

Thermal extraction and characterization of pectin from semi‐solid by‐products of the olive oil industry

Journal of the Science of Food and Agriculture, Volume 105, Issue 11, Page 5863-5873, 30 August 2025.
Abstract BACKGROUND The valorization of agro‐industrial by‐products is crucial for promoting sustainability and circular economy. Olive mill semi‐solid by‐products (OMSbP), also known as alperujo, contain valuable bioactive compounds, including pectin, which can be extracted and used in food applications.
Africa Fernandez‐Prior, Luna Barrera‐Chamorro, Elvira Marquez‐Paradas, Carol López‐de‐Dicastillo, Maria C. Millan‐Linares, Alvaro Villanueva‐Lazo, Sergio Montserrat‐de la Paz   +6 more
wiley   +1 more source

UEG Week 2023 Moderated Posters

, 2023
United European Gastroenterology Journal, Volume 11, Issue S8, Page 201-534, October 2023.
wiley   +1 more source

Biomolecular Affinities and Cytotoxicity of Copper(I) and Silver(I) Phosphine–Pyridinyl Complexes Against CACO‐2 and CASKI Cell Lines

European Journal of Inorganic Chemistry, Volume 28, Issue 15, May 28, 2025.
This study reports Copper(I) and Silver(I) complexes with pyridinyl Schiff base ligands and triphenylphosphine. Their DNA/protein binding and in vitro cytotoxicity were evaluated. All complexes intercalated with calf thymus DNA, bound strongly to proteins, and showed notable cytotoxicity against Caco‐2 and Caski cancer cells, highlighting their promise
Adesola A. Adeleke, Miche D. Meyer, Nicole R. S. Sibuyi, Martin O. Onani, Bernard Omondi   +4 more
wiley   +1 more source